Send to

Choose Destination
Iran J Psychiatry. 2010 Spring;5(2):47-50.

Femicomfort in the treatment of premenstrual syndromes: a double-blind, randomized and placebo controlled trial.

Author information

Infertility Center of Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran.



Premenstrual syndromes (PMS) affecting 20-40% of women of reproductive age. The aim of this double blind and placebo controlled trial was to investigate whether femicofort a supplement contains Vitamin B6, Vitamin E and evening primrose oil could relieve symptoms of PMS.


This was a randomized and double blind clinical trial. The trial was conducted between November 2009 and April March 2010. Women aged 20 to 45 years with regular menstrual cycles and experience of PMS symptoms (According to the current diagnostic criteria proposed by the American College of Obstetrics and Gynecology) for at least 6 months were eligible for the study. Patients were randomized to receive femicomfort or placebo in a 1: 1 ratio using a computer-generated code. The assignments were kept in sealed, opaque envelopes until the point of analysis of data. In this double-blind, patients were randomly assigned to receive capsule of femicomfort (Group A) or capsule placebo for two menstrual cycles (cycles 3 and 4). The primary outcome measure was the Daily Symptom Report, a checklist of 17 premenstrual symptoms rated from 0 to 4 according to their severity throughout the menstrual cycle. Secondary outcome measure was Hamilton Depression Rating Scale (17-item).


Femicomfort at this dose was found to be effective in relieving symptoms of PMS. The difference between the femicomfort and placebo in the frequency of side effects was not significant.


The results of this study indicate the efficacy of femicomfort in the treatment of PMS.


Oenothera biennis; Premenstrual syndrome; Vitamin B6; Vitamin E


Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center